---

Highlights of March 2019

1. Aurobindo completes acquisition of cancer drug portfolio from Spectrum Pharma in deal worth US$300 Million.
2. China’s HitGen in collaboration with India’s Sun Pharma to identify small molecule leads.
3. Allergan Acquires Envy Medical, Inc., adding Skin Resurfacing Dermal infusion System to Best-in-Class Medical Aesthetics Portfolio.
4. LegoChem Biosciences, Takeda collaborate for immuno-oncology research.
5. Celgene taps Exscientia’s AI drug discovery tech for 3 new programs with US$25 Million upfront.
6. Alexion and Zealand Pharma have teamed up to develop peptide therapies for complement-mediated diseases. Alexion will pay US$25 Million upfront to work with Zealand on the subcutaneously delivered therapies.
7. Stryker acquires OrthoSpace and its rotator cuff implant in US$220 Million deal.
8. Akili and Shionogi pair up to bring digital therapies to Japan and Taiwan in US$125 Million deal.
9. Adhera Therapeutics and Alyvant enter into Digital Co-Promotion Agreement for Prestalia, an approved therapy for the treatment of hypertension.
10. Taiwan Liposome Company and China’s 3SBio have announced an exclusive partnership to commercialize two liposomal products in mainland China.
11. Sagent buys U.S. sterile injectables plant in boost for parent Nichi-Iko.
12. Biogen is set to pay US$877 Million to buy Nightstar Therapeutics for its pipeline of gene therapies.

Updates at Aagami: 

1. New Client Win: South Korean Biotech appoints Aagami for out-licensing of their novel adjuvant in the US
2. Aagami to attend BIO International Convention 2019 in June. It’s Philadelphia this time. Meeting calendar opened.

Release Date: 10 March 2019